Difficulty: Medium
Average Score: 85%
Practice
Use of carbidopa along with levodopa in the treatment of parkinsonism
Correct answer
B
Rationale
Rationale:
The correct answer is B) Minimizes on-off effect.
Carbidopa is often used in combination with levodopa in the treatment of Parkinsonism. Carbidopa's primary role is to inhibit the peripheral decarboxylation of levodopa, allowing more levodopa to reach the brain where it can be converted to dopamine. This helps minimize the on-off effect commonly seen with levodopa therapy, where patients experience fluctuations in their symptoms.
Option A) Inhibits development of involuntary movements is incorrect because carbidopa does not directly inhibit the development of involuntary movements; rather, it helps improve the effectiveness of levodopa in managing these symptoms.
Option C) Inhibits occurrence of behavioral abnormalities is incorrect as carbidopa's main function is not related to the inhibition of behavioral abnormalities in Parkinsonism.
Option D) Accentuates nausea and vomiting is incorrect because carbidopa does not directly accentuate nausea and vomiting; in fact, it is often used in combination with levodopa to reduce gastrointestinal side effects associated with levodopa therapy.
Understanding the role of carbidopa in combination with levodopa is crucial for healthcare professionals managing patients with Parkinsonism. By preventing the peripheral breakdown of levodopa, carbidopa enhances the therapeutic effects of levodopa while reducing some of its side effects, such as the on-off phenomenon. This knowledge is essential for optimizing treatment outcomes and improving the quality of life for patients with Parkinsonism.
The correct answer is B) Minimizes on-off effect.
Carbidopa is often used in combination with levodopa in the treatment of Parkinsonism. Carbidopa's primary role is to inhibit the peripheral decarboxylation of levodopa, allowing more levodopa to reach the brain where it can be converted to dopamine. This helps minimize the on-off effect commonly seen with levodopa therapy, where patients experience fluctuations in their symptoms.
Option A) Inhibits development of involuntary movements is incorrect because carbidopa does not directly inhibit the development of involuntary movements; rather, it helps improve the effectiveness of levodopa in managing these symptoms.
Option C) Inhibits occurrence of behavioral abnormalities is incorrect as carbidopa's main function is not related to the inhibition of behavioral abnormalities in Parkinsonism.
Option D) Accentuates nausea and vomiting is incorrect because carbidopa does not directly accentuate nausea and vomiting; in fact, it is often used in combination with levodopa to reduce gastrointestinal side effects associated with levodopa therapy.
Understanding the role of carbidopa in combination with levodopa is crucial for healthcare professionals managing patients with Parkinsonism. By preventing the peripheral breakdown of levodopa, carbidopa enhances the therapeutic effects of levodopa while reducing some of its side effects, such as the on-off phenomenon. This knowledge is essential for optimizing treatment outcomes and improving the quality of life for patients with Parkinsonism.